Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Short Interest Update

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) was the target of a significant decline in short interest in May. As of May 15th, there was short interest totaling 19,598 shares, a decline of 57.4% from the April 30th total of 46,010 shares. Approximately 0.4% of the company’s stock are short sold. Based on an average daily volume of 28,089 shares, the days-to-cover ratio is currently 0.7 days.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on NEUP shares. Zacks Research upgraded shares of Neuphoria Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 3rd. HC Wainwright cut shares of Neuphoria Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 15th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $21.00.

Neuphoria Therapeutics Stock Performance

NEUP stock traded down $0.05 on Friday, hitting $5.31. 20,300 shares of the company’s stock were exchanged, compared to its average volume of 43,591. The firm has a 50 day moving average price of $4.84 and a two-hundred day moving average price of $4.44. Neuphoria Therapeutics has a 12-month low of $3.64 and a 12-month high of $21.40. The stock has a market cap of $28.67 million, a P/E ratio of -0.48 and a beta of 0.72.

Neuphoria Therapeutics (NASDAQ:NEUP) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.47. Sell-side analysts expect that Neuphoria Therapeutics will post -4.07 earnings per share for the current fiscal year.

Institutional Trading of Neuphoria Therapeutics

Institutional investors have recently bought and sold shares of the stock. AdvisorShares Investments LLC grew its position in Neuphoria Therapeutics by 15.8% during the 1st quarter. AdvisorShares Investments LLC now owns 155,367 shares of the company’s stock worth $632,000 after purchasing an additional 21,173 shares during the last quarter. XTX Topco Ltd acquired a new position in Neuphoria Therapeutics during the 4th quarter valued at approximately $47,000. Ikarian Capital LLC purchased a new position in shares of Neuphoria Therapeutics in the fourth quarter worth $184,000. Boothbay Fund Management LLC purchased a new position in shares of Neuphoria Therapeutics in the fourth quarter worth $54,000. Finally, Bridgeway Capital Management LLC acquired a new stake in shares of Neuphoria Therapeutics during the fourth quarter worth $57,000. 15.90% of the stock is currently owned by institutional investors and hedge funds.

Neuphoria Therapeutics Company Profile

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.